Download the Course Book (PDF)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(12) United States Patent (10) Patent No.: US 8,552,057 B2 Brinton Et Al
US008552057B2 (12) United States Patent (10) Patent No.: US 8,552,057 B2 Brinton et al. (45) Date of Patent: *Oct. 8, 2013 (54) PHYTOESTROGENIC FORMULATIONS FOR OTHER PUBLICATIONS ALLEVATION OR PREVENTION OF Morito et al. Interaction of Phytoestrogens with Estrogen Receptors NEURODEGENERATIVE DISEASES a and b (II). Biol. Pharm. Bull. 25(1), pp. 48-52 (2002).* Kinjo et al. Interactions of Phytoestrogens with Estrogen Receptors a (75) Inventors: Roberta Diaz, Brinton, Rancho Palos and b (III). Biol. Pharm. Bull. 27(2) pp. 185-188 (2004).* Verdes, CA (US); Liqin Zhao, Los An, et al., "Estrogen receptor -selective transcriptional activity and Angeles, CA (US) recruitment of coregulators by phytoestrogens', J Biol. Chem. 276(21): 17808-14 (2001). (73) Assignee: University of Southern California, Los Avis, et al. Is there a menopausal syndrome'? Menopausal status and symptoms across racial/ethnic groups', Soc. Sci. Med., 52(3):345-56 Angeles, CA (US) (2001). Brinton, et al. Impact of estrogen therapy on Alzheimer's disease: a (*) Notice: Subject to any disclaimer, the term of this fork in the road?’ CNS Drugs, 18(7):405-422 (2004). patent is extended or adjusted under 35 Bromberger, et al., Psychologic distress and natural menopause: a U.S.C. 154(b) by 0 days. multiethnic community study’. Am. J. Public Health, 91 (9) 1435-42 (2001). This patent is Subject to a terminal dis Brookmeyer, et al., “Projections of Alzheimer's disease in the United claimer. States and the public health impact of delaying disease onset'. Am. J. Public Health, 88(9): 1337-42 (1998). (21) Appl. -
The Evelyn F. and William L. Mcknight Brain Institute and the Cognitive Aging and Memory – Clinical Translational Research Program (CAM-CTRP) 2015 Annual Report
The Evelyn F. and William L. McKnight Brain Institute and the Cognitive Aging and Memory – Clinical Translational Research Program (CAM-CTRP) 2015 Annual Report Prepared for the McKnight Brain Research Foundation by the University of Florida McKnight Brain Institute and Institute on Aging Table of Contents Letter from UF Leadership ................................................................................................................................................................................................. 3 Age-related Memory Loss (ARML) Program and the Evelyn F. McKnight Chair for Brain Research in Memory Loss...... 4-19 Cognitive Aging and Memory Clinical Translational Research Program (CAM-CTRP) and the Evelyn F. McKnight Chair for Clinical Translational Research in Cognitive Aging and Memory ................................ 20-63 William G. Luttge Lectureship in Neuroscience ...............................................................................................................64-65 Program Financials .................................................................................................................................................................. 66 Age-related Memory Loss Program .............................................................................................................................................................................67 McKnight Endowed Chair for Brain Research in Memory Loss .........................................................................................................................68 -
Conceptive Estrus Behavior in Three Bottlenose Dolphins (Tursiops Truncatus)
Sciknow Publications Ltd. ABC 2015, 2(1):30-48 Animal Behavior and Cognition DOI: 10.12966/abc.02.03.2015 ©Attribution 3.0 Unported (CC BY 3.0) Conceptive Estrus Behavior in Three Bottlenose Dolphins (Tursiops truncatus) Holley Muraco1* and Stan A. Kuczaj II2 1Mississippi State University 2University of Southern Mississippi *Corresponding author (Email: [email protected]) Citation – Muraco, H., & Kuczaj, S. A. II. (2015). Conceptive estrus behavior in three bottlenose dolphins (Tursiops truncatus). Animal Behavior and Cognition, 2(1), 30-48. doi: 10.12966/abc.02.03.2015 Abstract - Bottlenose dolphins (Tursiops truncatus) are a highly promiscuous species that routinely engage in socio-sexual interactions, yet relatively little has been reported about actual estrus behavior. For this study of three female dolphins located at two aquarium facilities, 20 reproductive behaviors were investigated during three conceptive estrous cycles with known endocrinology. Reproductive behaviors increased with estradiol levels and peak occurrences of behaviors were observed during the luteinizing hormone (LH) surge. Two novel behaviors were observed: (1) genital tracking, an investigatory-type behavior, and (2) immobility, a novel form of standing heat estrus. These behaviors appeared to communicate reproductive readiness and increased copulation success. A total of 314 occurrences of estrus behavior were recorded in 10 hours of footage from the three focal females, and copulation spanned from day -9 to day 0 in one dominant female. Sexual interactions during estrus included female- to-female, immature male-to-female, mature male-to-immature male and masturbation with toys. During estrus, focal females received more behavioral attention than they initiated, and passive and active dorsal fin mounting between females was the most frequent behavior. -
NINDS Custom Collection II
ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC -
Us Anti-Doping Agency
2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used -
Part I Biopharmaceuticals
1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays -
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine -
(12) United States Patent (10) Patent No.: US 9,616,072 B2 Birrell (45) Date of Patent: *Apr
USOO961. 6072B2 (12) United States Patent (10) Patent No.: US 9,616,072 B2 Birrell (45) Date of Patent: *Apr. 11, 2017 (54) REDUCTION OF SIDE EFFECTS FROM 6,200,593 B1 3, 2001 Place AROMATASE INHIBITORS USED FOR 6,241,529 B1 6, 2001 Place 6,569,896 B2 5/2003 Dalton et al. TREATING BREAST CANCER 6,593,313 B2 7/2003 Place et al. 6,696,432 B1 2/2004 Elliesen et al. (71) Applicant: Chavah Pty Ltd, Medindie, South 6,995,284 B2 2/2006 Dalton et al. Australia (AU) 7,772.433 B2 8, 2010 Dalton et al. 8,003,689 B2 8, 2011 Veverka 8,008,348 B2 8, 2011 Steiner et al. (72) Inventor: Stephen Nigel Birrell, Medindie (AU) 8,980,569 B2 3/2015 Weinberg et al. 8,980,840 B2 3/2015 Truitt, III et al. (73) Assignee: CHAVAH PTY LTD., Stirling, South 9,150,501 B2 10/2015 Dalton et al. Australia (AU) 2003/0O87885 A1 5/2003 Masini-Eteve et al. 2004/O191311 A1 9/2004 Liang et al. *) Notice: Subject to anyy disclaimer, the term of this 2005/OO32750 A1 2/2005 Steiner et al. 2005/0176692 A1 8/2005 Amory et al. patent is extended or adjusted under 35 2005/0233970 A1 10/2005 Garnick U.S.C. 154(b) by 0 days. 2006, OO69067 A1 3/2006 Bhatnagar et al. 2007/0066568 A1 3/2007 Dalton et al. This patent is Subject to a terminal dis 2009,0264534 A1 10/2009 Dalton et al. claimer. 2010, O144687 A1 6, 2010 Glaser 2014, OO18433 A1 1/2014 Dalton et al. -
Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy † EVAN R
Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy † EVAN R. SIMPSON* AND MITCH DOWSETT *Prince Henry’s Institute of Medical Research, Monash Medical Centre, Clayton, Victoria 3168, Australia; †Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom ABSTRACT Endocrine adjuvant therapy for breast cancer in recent years has focussed primarily on the use of tamoxifen to inhibit the action of estrogen in the breast. The use of aromatase inhibitors has found much less favor due to poor efficacy and unsustainable side effects. Now, however, the situation is changing rapidly with the introduction of the so-called phase III inhibitors, which display high affinity and specificity towards aromatase. These compounds have been tested in a number of clinical settings and, almost without exception, are proving to be more effective than tamoxifen. They are being approved as first-line therapy for elderly women with advanced disease. In the future, they may well be used not only to treat young, postmenopausal women with early-onset disease but also in the chemoprevention setting. However, since these compounds inhibit the catalytic activity of aromatase, in principle, they will inhibit estrogen biosynthesis in every tissue location of aromatase, leading to fears of bone loss and possibly loss of cognitive function in these younger women. The concept of tissue-specific inhibition of aromatase expression is made possible by the fact that, in postmenopausal women when the ovaries cease to produce estrogen, estrogen functions primarily as a local paracrine and intracrine factor. Furthermore, due to the unique organization of tissue-specific promoters, regulation in each tissue site of expression is controlled by a unique set of regulatory factors. -
Table 1); Two in for Several Hours (Boccia Et Al., 2007)
Hormones and Behavior 57 (2010) 255–262 Contents lists available at ScienceDirect Hormones and Behavior journal homepage: www.elsevier.com/locate/yhbeh Manipulation of the oxytocin system alters social behavior and attraction in pair-bonding primates, Callithrix penicillata Adam S. Smith a,⁎, Anders Ågmo b, Andrew K. Birnie a, Jeffrey A. French a,c a Department of Psychology and Callitrichid Research Facility, University of Nebraska at Omaha, Omaha, Nebraska, USA b Department of Psychology, University of Tromsø, Norway c Department of Biology, University of Nebraska at Omaha, Omaha, Nebraska, USA article info abstract Article history: The establishment and maintenance of stable, long-term male-female relationships, or pair-bonds, are Received 12 August 2009 marked by high levels of mutual attraction, selective preference for the partner, and high rates of sociosexual Revised 3 December 2009 behavior. Central oxytocin (OT) affects social preference and partner-directed social behavior in rodents, but Accepted 8 December 2009 the role of this neuropeptide has yet to be studied in heterosexual primate relationships. The present study Available online 16 December 2009 evaluated whether the OT system plays a role in the dynamics of social behavior and partner preference during the first 3 weeks of cohabitation in male and female marmosets, Callithrix penicillata. OT activity was Keywords: Central oxytocin activity stimulated by intranasal administration of OT, and inhibited by oral administration of a non-peptide OT- Pair-bonding behavior receptor antagonist (L-368,899; Merck). Social behavior throughout the pairing varied as a function of OT Sexual behavior treatment. Compared to controls, marmosets initiated huddling with their social partner more often after OT Partner preference treatments but reduced proximity and huddling after OT antagonist treatments. -
Understanding Reproductive Events in the Mare for Successful Breeding Programs
Understanding Reproductive Events in the Mare for Successful Breeding Programs By Jillian Fain Bohlen, Department of Animal and Dairy Science Mare Cyclicity A solid understanding of mare cyclicity is the foundation on which to build or evaluate an equine breeding program. Horses differ from other species both in timing of cyclicity as well as endocrine patterns within a cycle. Basic principles can aid horse breeders in more effectively timing and breeding with or without hormone manipulation. Seasonally Polyestrus Mares are classified as seasonally polyestrous animals and are more generally termed “long day breeders.” This classification means mares cycle multiple times in the year but that these times are limited to when days are long. For the mare, this means conception prior to the hot days of summer and optimizing nutritional value for offspring by foaling early spring. This seasonality of the mare’s breeding cycle is mostly dictated by photoperiod; however, available food resources and temperature may also play minor roles. Lighting signals, associated with the photoperiod, are interpreted by the pineal gland and ultimately converted into endocrine signals. At the center of this pathway is melatonin. Melatonin secretion increases during the night phase and quickly decreases at the beginning of the day phase. In seasonal breeders such as sheep (short day) and horses (long day), melatonin has a large impact on when cyclicity will end and ultimately resume. This pattern for long day breeders is evident in Figure 1. In horses, low melatonin levels, which are associated with longer days, stimulate a cascade of hormones that ultimately control the ability of the mare to properly cycle. -
The Dichotomous Role of Inflammation in The
biomolecules Review The Dichotomous Role of Inflammation in the CNS: A Mitochondrial Point of View Bianca Vezzani 1,2 , Marianna Carinci 1,2 , Simone Patergnani 1,2 , Matteo P. Pasquin 1,2, Annunziata Guarino 2,3, Nimra Aziz 2,3, Paolo Pinton 1,2,4, Michele Simonato 2,3,5 and Carlotta Giorgi 1,2,* 1 Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy; [email protected] (B.V.); [email protected] (M.C.); [email protected] (S.P.); [email protected] (M.P.P.); [email protected] (P.P.) 2 Laboratory of Technologies for Advanced Therapy (LTTA), Technopole of Ferrara, 44121 Ferrara, Italy; [email protected] (A.G.); [email protected] (N.A.); [email protected] (M.S.) 3 Department of BioMedical and Specialist Surgical Sciences, University of Ferrara, 44121 Ferrara, Italy 4 Maria Cecilia Hospital, GVM Care & Research, 48033 Cotignola (RA), Italy 5 School of Medicine, University Vita-Salute San Raffaele, 20132 Milan, Italy * Correspondence: [email protected]; Tel.: +39-0532-455803 Received: 28 August 2020; Accepted: 10 October 2020; Published: 13 October 2020 Abstract: Innate immune response is one of our primary defenses against pathogens infection, although, if dysregulated, it represents the leading cause of chronic tissue inflammation. This dualism is even more present in the central nervous system, where neuroinflammation is both important for the activation of reparatory mechanisms and, at the same time, leads to the release of detrimental factors that induce neurons loss. Key players in modulating the neuroinflammatory response are mitochondria. Indeed, they are responsible for a variety of cell mechanisms that control tissue homeostasis, such as autophagy, apoptosis, energy production, and also inflammation.